What are the current Canadian guidelines for treating Helicobacter pylori infection in adults, including recommended first‑line regimens and options for treatment failure?

Canadian Guidelines for H. Pylori Treatment

For treatment-naive adults in Canada, use 14-day bismuth quadruple therapy (PPI + bismuth + metronidazole + tetracycline) or concomitant quadruple therapy (PPI + amoxicillin + metronidazole + clarithromycin) as first-line treatment, with bismuth quadruple therapy preferred given rising antibiotic resistance rates. 1

First-Line Treatment Approach

The 2016 Toronto Consensus—the definitive Canadian guideline—strongly recommends two primary first-line regimens, both given for 14 days 1:

Preferred First-Line Options:

Bismuth Quadruple Therapy (PBMT):

• Bismuth ~300mg four times daily
• Metronidazole 500mg three times daily
• Tetracycline 500mg four times daily
• PPI twice daily
• Duration: 14 days

Concomitant Therapy (PAMC):

• PPI twice daily
• Amoxicillin 1g twice daily
• Metronidazole 500mg twice daily
• Clarithromycin 500mg twice daily
• Duration: 14 days

Recent Canadian data from Edmonton (2016-2021) demonstrates that PAMC achieves 87% cure rates in newly diagnosed patients 2. However, clarithromycin resistance in Canada is alarmingly high at 78%, making bismuth quadruple therapy increasingly preferred when local resistance patterns are unknown 2.

Restricted First-Line Option:

PPI Triple Therapy (PPI + clarithromycin + amoxicillin OR metronidazole) should only be used in areas with documented clarithromycin resistance <15% 1. Given that Canadian clarithromycin resistance is 78%, this regimen is essentially obsolete for empiric use in Canada 2.

Critical Treatment Principles

All regimens must be 14 days—this is a strong recommendation based on antimicrobial stewardship principles 3, 1. The evidence clearly shows shorter durations are inadequate given current resistance patterns.

PPI dosing matters: Standard doses (pantoprazole 40mg, lansoprazole 30mg, omeprazole 20mg, esomeprazole 20mg) twice daily, taken 30 minutes before meals on an empty stomach 4.

Second-Line Treatment (After First Failure)

If first-line therapy fails, the approach depends on what was used initially 4:

After clarithromycin-based therapy failure:

• Use bismuth quadruple therapy (PBMT) for 14 days

After bismuth quadruple therapy failure:

• Use levofloxacin triple therapy (PPI + amoxicillin 1g twice daily + levofloxacin 500mg once daily) for 14 days
• Critical caveat: Canadian levofloxacin resistance has increased dramatically from 28% (2007-2015) to 61% (2016-2021) 2, making this less reliable

For penicillin allergy:

• Bismuth quadruple therapy remains appropriate (contains no penicillin)
• Levofloxacin-based regimens can be used

Third-Line and Salvage Therapy

After two treatment failures with confirmed adherence, obtain susceptibility testing before proceeding 4. This is a key recommendation to avoid further antibiotic misuse.

Rifabutin Triple Therapy (PAR):

• Rifabutin 150-300mg daily
• Amoxicillin 1g twice daily
• PPI twice daily
• Duration: 10 days

Canadian data shows rifabutin achieves only 50-57% cure rates 2, which is suboptimal. However, given the 61% levofloxacin resistance rate, consider rifabutin as third-line rather than fourth-line 2. The guideline traditionally reserves rifabutin for patients who have failed at least 3 prior regimens 4, but emerging resistance patterns may necessitate earlier use.

High-dose dual therapy (amoxicillin 2-3g daily in 3-4 split doses + high-dose PPI twice daily for 14 days) is an emerging option mentioned in recent guidelines 4.

Test of Cure

Mandatory for every patient: Perform urea breath test ≥4 weeks after completing therapy 3. This confirms eradication and provides indirect surveillance of local resistance patterns.

Common Pitfalls to Avoid

1. Don't use 7-10 day regimens—14 days is now standard for all therapies 1

2. Don't use clarithromycin triple therapy empirically—78% resistance in Canada makes this ineffective 2

3. Don't skip test of cure—this is essential for confirming eradication and tracking resistance 3

4. Don't use levofloxacin empirically after one failure—61% resistance means it should be susceptibility-guided 2

5. Don't prescribe concomitant therapy without understanding it includes unnecessary antibiotics—at least one antibiotic in these regimens plays no role in treatment outcome, contributing to global resistance 3

Algorithmic Approach for Canadian Practice

Newly diagnosed H. pylori:

1. First-line: Bismuth quadruple therapy × 14 days (preferred) OR concomitant therapy × 14 days
2. Test of cure at ≥4 weeks

First treatment failure:

1. Confirm adherence
2. If used clarithromycin-based → switch to bismuth quadruple therapy × 14 days
3. If used bismuth quadruple → consider levofloxacin triple × 14 days (with caution given 61% resistance)
4. Test of cure at ≥4 weeks

Second treatment failure:

1. Obtain susceptibility testing
2. Consider rifabutin triple therapy × 10 days (earlier than traditional fourth-line given levofloxacin resistance)
3. Use susceptibility-guided therapy if testing available
4. Test of cure at ≥4 weeks

The Canadian data demonstrates that algorithmic treatment following these guidelines cures 88% of newly diagnosed patients but only 75% of those with previous treatment failures 2, emphasizing the critical importance of getting first-line therapy right.